No Data
No Data
Express News | Gain Therapeutics Shares Are Trading Higher After Oppenheimer Issued an Outperform Rating on the Stock and Announced a Price Target of $8
Oppenheimer Adjusts Gain Therapeutics Price Target to $8 From $9
Express News | Gain Therapeutics, Inc. : Oppenheimer Cuts Target Price to $8 From $9
Express News | Gain Therapeutics Inc : Oppenheimer Assumes Coverage With Outperform Rating; Target Price $8 Vs $9
Express News | Chardan Capital Maintains Buy on Gain Therapeutics, Maintains $6 Price Target
Buy Rating Affirmed for Gain Therapeutics on GT-02287 Clinical Progress and Robust Financial Health
No Data
Taco moo-ncher : what happened to your "hehehehe" uh?
Trytosaveabit OP Taco moo-ncher : Well I guess I just didn’t find anything humorous to laugh at with this post! Hehehe
Taco moo-ncher Trytosaveabit OP : ok![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)